Physician profile
Eric T Wong
NPI 1437179199
$41,917.21
in general payments reported to CMS, 2019-2025
12 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2021: $2,797 · 2022: $1,678 · 2023: $6,327 · 2024: $1,629 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Honoraria: $6,000 · Food and Beverage: $1,908 · Travel and Lodging: $1,721 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,800.00 |
| Honoraria | $6,000.00 |
| Food and Beverage | $1,907.63 |
| Travel and Lodging | $1,720.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25,800.00 | 2025 | |
| Novocure INC. | $11,229.26 | 2019-2025 | Optune, Optune Gio |
| Pfizer INC. | $3,028.79 | 2024-2025 | |
| Telix Pharmaceuticals | $1,222.00 | 2024-2025 | Illuccix |
| Agios Pharmaceuticals, INC. | $184.60 | 2019 | |
| Merck Sharp & Dohme LLC | $146.44 | 2022 | |
| Kyowa Kirin, INC. | $124.24 | 2022 | |
| Janssen Biotech, INC. | $63.22 | 2025 | Carvykti, Rybrevant |
| Abbvie INC. | $61.95 | 2025 | |
| Biogen, INC. | $42.32 | 2019 | |
| Novo Nordisk INC | $14.39 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.